From SourceWatch
(Redirected from Fibrogen)
Jump to navigation Jump to search
This article is a stub. You can help by expanding it.

"FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs." [1]


Accessed December 2010: [2]

  • Thomas B. Neff - Chairman, Founder, Chief Executive Officer
  • Thomas F. Kearns, Jr. - Retired Partner, Bear, Stearns & Co., Inc.
  • Kalevi Kurkijärvi - Senior Partner, Chairman and CEO, BioFund Management Fund Ltd.
  • Miguel Madero - Fomento Direccion, Mexico
  • Rory B. Riggs - Managing Member, Balfour LLC; Former President and Director, Biomatrix, Inc.
  • Roberto Pedro Rosenkranz - Chairman and Chief Executive Officer, ROXRO PHARMA, Inc.; Director, Pherin Pharmaceuticals
  • Jorma Routti - Chairman of the Board of Directors, FibroGen Europe, Former Director General of the Directorate of Science, Research and Development of the European Commission
  • James A. Schoeneck - CEO and Director, BrainCells Inc.
  • Julian N. Stern - Counsel to Goodwin Procter, LLP.
  • Toshinari Tamura - Former Representative Director, Executive Vice President and Chief Science Officer of Astellas Pharma, Inc.



Resources and articles

Related Sourcewatch


  1. Home, FibroGen, accessed December 10, 2010.
  2. People, FibroGen, accessed December 10, 2010.